Sanofi (BIT:1SAN)
Italy
· Delayed Price · Currency is EUR | Market Cap | 99.26B |
| Revenue (ttm) | 46.72B |
| Net Income (ttm) | 7.81B |
| Shares Out | n/a |
| EPS (ttm) | 6.37 |
| PE Ratio | 12.70 |
| Forward PE | 9.85 |
| Dividend | 3.92 (4.94%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 3,374 |
| Average Volume | 2,927 |
| Open | 81.90 |
| Previous Close | 80.97 |
| Day's Range | 81.20 - 82.18 |
| 52-Week Range | 76.42 - 111.00 |
| Beta | 0.37 |
| RSI | 58.39 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion fo...
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ta...
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 s...
How Do Investors Really Feel About Sanofi SA?
Sanofi SA's (NYSE: SNY) short interest as a percent of float has fallen 5.13% since its last report. According to exchange reported data, there are now 7.94 million shares sold short , which is 0.37%...
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earning...
FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis
(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis who have a his...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) partnered Dupixent (dupilumab) for treating allergic fungal rhinos...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis
Sanofi (SNY) Gains FDA Approval for Dupixent in New Treatment Area
Sanofi (SNY) Gains FDA Approval for Dupixent in New Treatment Area
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d...
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d...
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics' Oversubscribed Series A, Bringing Total Financing to $197 Million
Proceeds from the financing will advance the Phase 2 clinical development of Alveus' lead program ALV ‑ 100 designed to deliver potent, durable weight loss and long ‑ term maintenance with improved to...
Sanofi (SNY) Faces Legal Action Over Alleged Kickback Scheme
Sanofi (SNY) Faces Legal Action Over Alleged Kickback Scheme
Sanofi sued by Texas AG for running kickback scheme for doctors
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.
Oakmark Fund Adds Sanofi (SNY) to Portfolio in Q4 2025
Oakmark Fund Adds Sanofi (SNY) to Portfolio in Q4 2025
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Sanofi, Teva Report Positive Phase 2b Results For Duvakitug
(RTTNews) - Sanofi SA (SNY) and Teva Pharmaceutical Industries Ltd. (TEVA) reported on Tuesday, positive long-term extension data from the phase 2b RELIEVE UCCD study of duvakitug in ulcerative coliti...
Sanofi announces leadership evolution in Specialty Care Business Unit
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026.
Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) will hold an investor call and webcast today to highlight new Phase 2b maintenance data for Duvakitug. The investigational thera...
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study. Positive Data Fr...